Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 8, 2001

View Archived Issues

Licensing opportunity from NIH: virus-like particles as unlinked adjuvants

Topically applied CDK2 inhibitor prevents chemotherapy-induced hair loss

Role of PPARs and their ligands in atherogenesis incites a flurry of research

Abgenix plans to move ABX-IL-8 into phase IIb clinical trials for psoriasis

Sepracor pharmaceutical products portfolio update

Lexicon Genetics and Abgenix establish drug target validation collaboration

Oxford BioMedica initiates phase I/II clinical trial of TroVax as treatment of colorectal cancer

Phase IIb study of TP-10 in infants undergoing high-risk cardiac surgery now under way

Anti-EGF MAb produces clinical, biochemical improvement in patient with Menetrier's disease

Elan prepares launch of Myocet in Europe

Vertex commences phase II trial of VX-745 for rheumatoid arthritis

Positive final results emerge from INS-1 trial for type 2 diabetes

Antiinflammatory and antiemetic effects of YM-976 evaluated in animal studies

Macrolide antimicrobial agents related to erythromycin prepared at Abbott

Selective inhibitors of cathepsin S designed jointly by Medivir and Peptimmune

Patent issued to Hokuriku covering new antibacterial series

CeNeS licenses North American rights for Moraxen to Amarin; additional phase III study planned

Sumitomo presents new ECE inhibitors and their potential uses

Naturally produced compounds with antiplatelet and other properties discovered by Teijin

New series of sphingomyelinase inhibitors described by Ono researchers

Phase II head and neck cancer trial of Multikine cleared in Mexico

Antiinflammatory compounds from Bayer act as PDE4 inhibitors

Marketing agreement with Bioglan for Solaraze expanded by SkyePharma

Phase II IDEC-131 study begins in patients with ITP

Generex and Elan to form joint venture

Amarillo Biosciences reports completion of IFN-alpha phase III trial in Sjogren's syndrome

University of Pittsburgh awarded NHLBI grant for cardiovascular gene therapy program

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...